Business Description
Dicot Pharma AB
SIC : 2834
ISIN : SE0011178458
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
DICOT.SwedenKN0.Germany IPO Date
2018-06-20Description
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40 | |||||
3-Year EPS without NRI Growth Rate | 40.4 | |||||
3-Year FCF Growth Rate | 37.5 | |||||
3-Year Book Growth Rate | 24.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.57 | |||||
9-Day RSI | 46.51 | |||||
14-Day RSI | 51.61 | |||||
3-1 Month Momentum % | -7.2 | |||||
6-1 Month Momentum % | -49.96 | |||||
12-1 Month Momentum % | -71.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 30.69 | |||||
Quick Ratio | 29.37 | |||||
Cash Ratio | 28.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -92.6 | |||||
Shareholder Yield % | -26.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -56.62 | |||||
ROA % | -51.68 | |||||
ROIC % | -529.39 | |||||
3-Year ROIIC % | -777.18 | |||||
ROC (Joel Greenblatt) % | -2680 | |||||
ROCE % | -57.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.13 | |||||
Price-to-Tangible-Book | 3.32 | |||||
EV-to-EBIT | -8.31 | |||||
EV-to-EBITDA | -8.31 | |||||
EV-to-FCF | -8.51 | |||||
| Price-to-Net-Current-Asset-Value | 3.32 | |||||
| Price-to-Net-Cash | 3.32 | |||||
Earnings Yield (Greenblatt) % | -12.04 | |||||
FCF Yield % | -8.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dicot Pharma AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.03 | ||
| Beta | 0.5758 | ||
| 3-Year Sharpe Ratio | 0.67 | ||
| 3-Year Sortino Ratio | 1.37 | ||
| Volatility % | 81.22 | ||
| 14-Day RSI | 51.61 | ||
| 14-Day ATR (kr) | 0.014613 | ||
| 20-Day SMA (kr) | 0.23452 | ||
| 12-1 Month Momentum % | -71.38 | ||
| 52-Week Range (kr) | 0.175 - 1.051025 | ||
| Shares Outstanding (Mil) | 3,468.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dicot Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dicot Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 145 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 38 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | 0.22 (-1.43%) | ||
| General meeting for 2025 | 2026-05-06 | 0.26 (+4.78%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 0.26 (-4.81%) | ||
| Annual report for 2025 | 2026-04-10 | 0.36 (-0.35%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-18 | 0.27 (-4.72%) | ||
| Third quarter earnings results for 2025 | 2025-10-22 | 0.85 (-3.95%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 0.61 (+0.44%) | ||
| General meeting for 2024 | 2025-05-06 17:00 | 0.31 (+1.59%) |
Show
Entries
Dicot Pharma AB Frequently Asked Questions
What is Dicot Pharma AB(OSTO:DICOT)'s stock price today?
The current price of OSTO:DICOT is kr0.23. The 52 week high of OSTO:DICOT is kr1.05 and 52 week low is kr0.18.
When is next earnings date of Dicot Pharma AB(OSTO:DICOT)?
The next earnings date of Dicot Pharma AB(OSTO:DICOT) is 2026-10-28.
Does Dicot Pharma AB(OSTO:DICOT) pay dividends? If so, how much?
Dicot Pharma AB(OSTO:DICOT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers